992 related articles for article (PubMed ID: 28426845)
1. HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial.
Ahmed N; Brawley V; Hegde M; Bielamowicz K; Kalra M; Landi D; Robertson C; Gray TL; Diouf O; Wakefield A; Ghazi A; Gerken C; Yi Z; Ashoori A; Wu MF; Liu H; Rooney C; Dotti G; Gee A; Su J; Kew Y; Baskin D; Zhang YJ; New P; Grilley B; Stojakovic M; Hicks J; Powell SZ; Brenner MK; Heslop HE; Grossman R; Wels WS; Gottschalk S
JAMA Oncol; 2017 Aug; 3(8):1094-1101. PubMed ID: 28426845
[TBL] [Abstract][Full Text] [Related]
2. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study.
Cruz CR; Micklethwaite KP; Savoldo B; Ramos CA; Lam S; Ku S; Diouf O; Liu E; Barrett AJ; Ito S; Shpall EJ; Krance RA; Kamble RT; Carrum G; Hosing CM; Gee AP; Mei Z; Grilley BJ; Heslop HE; Rooney CM; Brenner MK; Bollard CM; Dotti G
Blood; 2013 Oct; 122(17):2965-73. PubMed ID: 24030379
[TBL] [Abstract][Full Text] [Related]
3. Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma.
Ahmed N; Brawley VS; Hegde M; Robertson C; Ghazi A; Gerken C; Liu E; Dakhova O; Ashoori A; Corder A; Gray T; Wu MF; Liu H; Hicks J; Rainusso N; Dotti G; Mei Z; Grilley B; Gee A; Rooney CM; Brenner MK; Heslop HE; Wels WS; Wang LL; Anderson P; Gottschalk S
J Clin Oncol; 2015 May; 33(15):1688-96. PubMed ID: 25800760
[TBL] [Abstract][Full Text] [Related]
4. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.
Lee DW; Kochenderfer JN; Stetler-Stevenson M; Cui YK; Delbrook C; Feldman SA; Fry TJ; Orentas R; Sabatino M; Shah NN; Steinberg SM; Stroncek D; Tschernia N; Yuan C; Zhang H; Zhang L; Rosenberg SA; Wayne AS; Mackall CL
Lancet; 2015 Feb; 385(9967):517-528. PubMed ID: 25319501
[TBL] [Abstract][Full Text] [Related]
5. Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor-transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma.
Goff SL; Morgan RA; Yang JC; Sherry RM; Robbins PF; Restifo NP; Feldman SA; Lu YC; Lu L; Zheng Z; Xi L; Epstein M; McIntyre LS; Malekzadeh P; Raffeld M; Fine HA; Rosenberg SA
J Immunother; 2019 May; 42(4):126-135. PubMed ID: 30882547
[TBL] [Abstract][Full Text] [Related]
6. Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis.
Vitanza NA; Johnson AJ; Wilson AL; Brown C; Yokoyama JK; Künkele A; Chang CA; Rawlings-Rhea S; Huang W; Seidel K; Albert CM; Pinto N; Gust J; Finn LS; Ojemann JG; Wright J; Orentas RJ; Baldwin M; Gardner RA; Jensen MC; Park JR
Nat Med; 2021 Sep; 27(9):1544-1552. PubMed ID: 34253928
[TBL] [Abstract][Full Text] [Related]
7. CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges.
Bagley SJ; Desai AS; Linette GP; June CH; O'Rourke DM
Neuro Oncol; 2018 Oct; 20(11):1429-1438. PubMed ID: 29509936
[TBL] [Abstract][Full Text] [Related]
8. Early transduction produces highly functional chimeric antigen receptor-modified virus-specific T-cells with central memory markers: a Production Assistant for Cell Therapy (PACT) translational application.
Sun J; Huye LE; Lapteva N; Mamonkin M; Hiregange M; Ballard B; Dakhova O; Raghavan D; Durett AG; Perna SK; Omer B; Rollins LA; Leen AM; Vera JF; Dotti G; Gee AP; Brenner MK; Myers DG; Rooney CM
J Immunother Cancer; 2015; 3():5. PubMed ID: 25734008
[TBL] [Abstract][Full Text] [Related]
9. Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape.
Hegde M; Mukherjee M; Grada Z; Pignata A; Landi D; Navai SA; Wakefield A; Fousek K; Bielamowicz K; Chow KK; Brawley VS; Byrd TT; Krebs S; Gottschalk S; Wels WS; Baker ML; Dotti G; Mamonkin M; Brenner MK; Orange JS; Ahmed N
J Clin Invest; 2016 Aug; 126(8):3036-52. PubMed ID: 27427982
[TBL] [Abstract][Full Text] [Related]
10. Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes.
Ramos CA; Ballard B; Zhang H; Dakhova O; Gee AP; Mei Z; Bilgi M; Wu MF; Liu H; Grilley B; Bollard CM; Chang BH; Rooney CM; Brenner MK; Heslop HE; Dotti G; Savoldo B
J Clin Invest; 2017 Sep; 127(9):3462-3471. PubMed ID: 28805662
[TBL] [Abstract][Full Text] [Related]
11. Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma.
Brown CE; Badie B; Barish ME; Weng L; Ostberg JR; Chang WC; Naranjo A; Starr R; Wagner J; Wright C; Zhai Y; Bading JR; Ressler JA; Portnow J; D'Apuzzo M; Forman SJ; Jensen MC
Clin Cancer Res; 2015 Sep; 21(18):4062-72. PubMed ID: 26059190
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers.
Feng K; Liu Y; Guo Y; Qiu J; Wu Z; Dai H; Yang Q; Wang Y; Han W
Protein Cell; 2018 Oct; 9(10):838-847. PubMed ID: 28710747
[TBL] [Abstract][Full Text] [Related]
13. Intracranial injection of natural killer cells engineered with a HER2-targeted chimeric antigen receptor in patients with recurrent glioblastoma.
Burger MC; Forster MT; Romanski A; Straßheimer F; Macas J; Zeiner PS; Steidl E; Herkt S; Weber KJ; Schupp J; Lun JH; Strecker MI; Wlotzka K; Cakmak P; Opitz C; George R; Mildenberger IC; Nowakowska P; Zhang C; Röder J; Müller E; Ihrig K; Langen KJ; Rieger MA; Herrmann E; Bonig H; Harter PN; Reiss Y; Hattingen E; Rödel F; Plate KH; Tonn T; Senft C; Steinbach JP; Wels WS
Neuro Oncol; 2023 Nov; 25(11):2058-2071. PubMed ID: 37148198
[TBL] [Abstract][Full Text] [Related]
14. Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2
Priceman SJ; Tilakawardane D; Jeang B; Aguilar B; Murad JP; Park AK; Chang WC; Ostberg JR; Neman J; Jandial R; Portnow J; Forman SJ; Brown CE
Clin Cancer Res; 2018 Jan; 24(1):95-105. PubMed ID: 29061641
[No Abstract] [Full Text] [Related]
15. Autologous T-cell therapy for cytomegalovirus as a consolidative treatment for recurrent glioblastoma.
Schuessler A; Smith C; Beagley L; Boyle GM; Rehan S; Matthews K; Jones L; Crough T; Dasari V; Klein K; Smalley A; Alexander H; Walker DG; Khanna R
Cancer Res; 2014 Jul; 74(13):3466-76. PubMed ID: 24795429
[TBL] [Abstract][Full Text] [Related]
16. PiggyBac-mediated cancer immunotherapy using EBV-specific cytotoxic T-cells expressing HER2-specific chimeric antigen receptor.
Nakazawa Y; Huye LE; Salsman VS; Leen AM; Ahmed N; Rollins L; Dotti G; Gottschalk SM; Wilson MH; Rooney CM
Mol Ther; 2011 Dec; 19(12):2133-43. PubMed ID: 21772253
[TBL] [Abstract][Full Text] [Related]
17. Chimeric Antigen Receptor Signaling Domains Differentially Regulate Proliferation and Native T Cell Receptor Function in Virus-Specific T Cells.
Omer B; Castillo PA; Tashiro H; Shum T; Huynh MTA; Cardenas M; Tanaka M; Lewis A; Sauer T; Parihar R; Lapteva N; Schmueck-Henneresse M; Mukherjee M; Gottschalk S; Rooney CM
Front Med (Lausanne); 2018; 5():343. PubMed ID: 30619856
[TBL] [Abstract][Full Text] [Related]
18. HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors.
Ahmed N; Salsman VS; Kew Y; Shaffer D; Powell S; Zhang YJ; Grossman RG; Heslop HE; Gottschalk S
Clin Cancer Res; 2010 Jan; 16(2):474-85. PubMed ID: 20068073
[TBL] [Abstract][Full Text] [Related]
19. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma.
O'Rourke DM; Nasrallah MP; Desai A; Melenhorst JJ; Mansfield K; Morrissette JJD; Martinez-Lage M; Brem S; Maloney E; Shen A; Isaacs R; Mohan S; Plesa G; Lacey SF; Navenot JM; Zheng Z; Levine BL; Okada H; June CH; Brogdon JL; Maus MV
Sci Transl Med; 2017 Jul; 9(399):. PubMed ID: 28724573
[TBL] [Abstract][Full Text] [Related]
20. Current progress in chimeric antigen receptor T cell therapy for glioblastoma multiforme.
Marei HE; Althani A; Afifi N; Hasan A; Caceci T; Pozzoli G; Cenciarelli C
Cancer Med; 2021 Aug; 10(15):5019-5030. PubMed ID: 34145792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]